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Abstract 
Background: Tasquinimod is a small molecule with immunomodulatory, anti-
angiogenic and anti-metastatic properties that targets the tumour microenvironment.  
It has previously been evaluated in patients with metastatic prostate cancer.  This study 
aimed to obtain a clinical proof of concept that tasquinimod was active and tolerable in 
patients with other advanced solid tumours. 
Patients and methods: This early stopping design, open-label, proof-of-concept 
clinical trial evaluated the clinical activity of tasquinimod in four independent cohorts 
of patients with advanced hepatocellular (n = 53), ovarian (n = 55), renal cell (n = 38) 
and gastric (n = 21) cancers that had progressed during or after standard therapies. 
Patients received tasquinimod 0.5 mg/day once daily for at least 2 weeks, with the 
dose then increased to 1 mg/day. Tasquinimod was given until radiological disease 
progression according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 
criteria, intolerable toxicity or patient withdrawal. The primary efficacy end point was 
the progression-free survival (PFS) rate according to RECIST 1.1 by central 
assessment. 
Results: Interim futility analyses at 8 weeks (6 weeks for the gastric cancer cohort) 
found adequate clinical activity of tasquinimod only in the hepatocellular cohort and 
recruitment to the other three cohorts was stopped. At final analysis, PFS rates were 
26.9 at 16 weeks, 7.3 at 24 weeks, 13.2 at 16 weeks and 9.5% at 12 weeks, 
respectively, in hepatocellular, ovarian, renal cell and gastric cancer cohorts. In all 
patients, the most common treatment-emergent adverse events related to treatment 
were fatigue (48.5%), nausea (34.1%), decreased appetite (31.7%), and vomiting 
(24.6%). 
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Conclusions: Clinical activity of tasquinimod in heavily pre-treated patients with 
advanced hepatocellular, ovarian, renal cell and gastric cancer was not sufficient to 
warrant further clinical investigation. 
Trial registration: NCT01743469 
Key words: gastric cancer, hepatocellular cancer, ovarian cancer, PFS, renal cell 
cancer, tasquinimod 
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Introduction 
Tasquinimod is a second-generation oral quinoline-3-carboxamide with multiple effects 
in the tumour microenvironment that inhibit tumour growth and metastasis [1]. A key 
target of tasquinimod is S100A9, a multifunctional immunomodulatory protein found in 
high levels in the microenvironment of several tumour types [2], which interacts with 
the proinflammatory receptors, such as Toll-like receptor 4, expressed on myeloid-
derived suppressor cells (MDSCs), macrophages, endothelial and other cells. MDSCs 
in the tumour microenvironment stimulate angiogenesis using both vascular 
endothelial growth factor (VEGF)-dependent and VEGF-independent mechanisms [3].  
Studies show improved progression-free survival (PFS) in patients with 
metastatic castration-resistant prostate cancer (mCRPC) treated with tasquinimod [4, 
5]. Resistance to treatment and disease relapse or progression is common in 
hepatocellular, ovarian, renal cell and gastric cancers. Angiogenesis is significantly 
involved in the development of these four tumour types, and resistance to 
angiogenesis inhibitors thought to occur by tumour cell adaptation through 
upregulation of pre-existing redundant or evasive mechanisms [6].  
This study was undertaken to obtain clinical proof-of-concept that tasquinimod 
was active and tolerable in patients with advanced hepatocellular (HCC), epithelial 
ovarian (OC), renal cell carcinoma (RCC) or gastric cancers (GC). 
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Patients and methods 
This phase II, open-label, proof-of-concept clinical trial (ClinicalTrials.gov identifier 
NCT01743469) was performed at 24 sites in Belgium, Canada, France, Spain and the 
UK (see Supplementary Material Table S1 available online). The study was conducted 
under the provisions of the Declaration of Helsinki, and in accordance with the 
International Conference on Harmonisation Consolidated Guideline on Good Clinical 
Practice. The protocol and amendments and documents for patients were reviewed 
and approved by an independent ethics committee or institutional review board prior 
to study start. 
 
Study participants and treatment 
The study included adult patients with histologically confirmed advanced HCC, OC, 
RCC and GC who had progressed during or after standard therapies. Full inclusion 
and exclusion criteria are provided in supplementary Table S2. All patients were to 
receive tasquinimod at a starting dose of 0.5 mg/day maintained for at least 2 weeks 
and then increased to 1 mg/day. The dose could be maintained or reduced in case of 
Treatment Emergent Adverse Events (TEAEs). 
 
Study plan and design  
Tasquinimod treatment was given until radiological disease progression according to 
Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria [7], toxicity or 
patient withdrawal. Full details of study visit schedule and clinical assessments are 
provided in Tables S3 and S4 in the Supplementary Material available online. 
 
Sample size 
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This study used a two-stage early stopping design (with a futility analysis at stage 1) 
to assess the activity of tasquinimod based on the proportion of patients who had 
neither progressed nor died at predefined time points (the PFS rate [8]) in each of four 
cohorts. For each cohort, the sample size was calculated based on a one-sided α of 
≤0.1 and a power of ≥90% together with the constraints that the chance of early 
stopping given the null hypothesis (i.e. tasquinimod showed inadequate clinical 
activity) was ≥50% and the chance of early stopping given the alternative hypothesis 
was ≤10%. 
The interim futility analysis was performed for each cohort after a predefined 
number of patients reached Week 8 (Week 6 for the GC cohort; T1). If the number of 
patients who had neither progressed nor died at this time was lower than expected so 
the null hypothesis was not rejected, recruitment would be stopped; otherwise, 
recruitment continued. The expected PFS rate for an active treatment at T1 (and to 
pursue the recruitment until T2) was 60% for the HCC, 65% for the OC and RCC and 
40% for the GC cohort. At T2 the expected PFS rates for an active treatment were 40% 
for both the HCC and RCC cohorts at 16 weeks, 55% for the ovarian cancer (OC) 
cohort at 24 weeks and 35% for the gastric cancer (GC) cohort at 12 weeks. The cohort 
patient numbers, analysis timings and expected PFS rates are shown in 
Supplementary Material Table S5. 
 
Efficacy and safety end points and assessments 
The primary efficacy end point was the proportion of patients who neither progressed 
nor died (PFS rate) according to RECIST v1.1 by central assessment at the final 
analysis (T2; see Supplementary Material Table S5 for time points). Secondary 
efficacy end points were PFS duration, response rate, clinical benefit, time to 
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progression (TTP), and overall survival (OS). A patient was considered to have had 
clinical benefit if a complete response, a partial response or stable disease was 
observed for ≥12 weeks after the first study medication according to RECIST criteria. 
All tumour assessments were appraised by investigators and then secondly by a 
central independent reviewer. Overall response was evaluated using the RECIST v1.1 
guideline for all cohorts and also by Choi criteria in HCC cohort. 
Safety assessments were performed regularly throughout the study: adverse 
events (AEs), laboratory test values, ECOG performance status, vital signs and 12-
lead electrocardiographic findings were monitored and recorded. AEs and laboratory 
tests were graded using the National Cancer Institute Common Terminology Criteria 
for Adverse Events (NCI-CTCAE) classification version 4.03 (or severity) and coded 
using MedDRA dictionary. 
A range of blood biomarkers of angiogenesis, immunomodulation and 
inflammation at screening and regularly during the study treatment, tumour tissues 
(archive or biopsy) at screening and 4 weeks after tasquinimod start (cohort HCC only) 
were also assessed (see Supplementary Material Tables S3 and S4). Biomarker data 
were analysed for investigational objectives exploring the potential association of 
biomarkers with drug effects, such as PFS duration, clinical benefit and TEAEs, to 
better characterise the tumour types in each patient cohort and the mechanism of 
action of tasquinimod.  
 
Statistical analysis 
Efficacy and safety analyses were performed on all patients receiving at least 1 dose 
of tasquinimod. The primary efficacy analysis was the PFS rate (presented with its 95% 
confidence interval (CI) calculated using the Clopper-Pearson exact method) 
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according to RECIST v1.1 by central assessment at the final analysis (T2). For each 
cohort, the primary analysis was performed at T2 by comparing the PFS rate with the 
prespecified threshold using a one-sided α of 0.1. For analysis of the time dependent 
parameters as PFS, TTP and OS, the Kaplan-Meier method was used. 
Safety data were analysed for the Safety Population, separately for each cohort 
and in an overall pooled analysis at T2. The safety analysis was based on treatment 
emergent AEs (TEAEs). For each TEAEs, worst NCI CTCAE (Version 4.03); grade per 
patient was tabulated by System Organ Class (SOC) and Preferred Term (PT). 
Laboratory values were presented by worst NCI CTCAE grade per patient or 
descriptive statistics. 
 
Results 
Patients and treatment 
From December 2012 to July 2014, 201 patients were screened and 167 patients 
subsequently enrolled in the four separate cohorts. There were 53 patients with HCC, 
55 patients with OC, 38 patients with RCC and 21 patients with GC. The original 
planned total for the HCC cohort was 52 but due to an additional ongoing enrolment, 
this number increased to 53. Patient disposition through the study is shown in Figure 
1 and demographic and selected clinical characteristics in the four separate cohorts at 
baseline are shown in Table S6 in the Supplementary Material. 
Dose escalation to 1 mg/day was achieved in the majority of patients (62–77%), 
while few required a reduction of treatment dose. The median duration of treatment 
ranged from 5.9 weeks in the GC cohort to 9.4 weeks in the HCC cohort (Table S7 in 
the Supplementary Material). 
 
Efficacy 
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For the HCC cohort, the observed PFS rate at T1 was superior to the predefined rate 
required to proceed and more patients were enrolled up to the planned total (plus one 
additional patient - see above). For the OC cohort, recruitment as planned was 
completed before the T1 futility analysis results were available. For the RCC and GC 
cohorts, the pre-specified PFS rate was not achieved and further recruitment was 
stopped. 
The results presented correspond to the final analysis of all patients enrolled 
and treated at 12 weeks for the gastric cohort, 16 weeks for renal and hepatic cohorts 
and 24 weeks for the ovarian cohort. Clinical efficacy parameters are shown in Table 
1 for all four cohorts. None of the PFS rates at T2 reached the predefined threshold for 
efficacy.  
Kaplan-Meier estimates of PFS and OS in the HCC cohort (n = 53) based on 
central review showed a median (95% CI) of 15.9 (8.0–23.1) and 29.3 (25.0–38.7) 
weeks, respectively (Figure 2).  
 
Safety 
All patients experienced at least one TEAE (Table 2); serious TEAEs occurred in 26–
35% of patients (Table S8 in the Supplemental Material). The majority of TEAEs were 
considered related to study treatment, but most were low grade. Across all patients, 
the most common TEAEs related to treatment were fatigue (48.5%), nausea (34.1%), 
decreased appetite (31.7%), and vomiting (24.6%). 
In all four cohorts, changes in laboratory parameters of grade 3 severity were 
experienced by less than 5% of patients. Increases in liver function tests were reported 
in 14 patients (26.9%) in the HCC cohort and occasionally in the other three cohorts. 
Of particular interest in this study were blood levels of amylase and lipase. Abnormal 
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increases of grade 3 or higher severity were noted in 22 patients for lipase and five 
patients for amylase (see Table S9 in the Supplementary Material). 
 
Exploratory analyses 
Multivariate analyses of PFS relative to baseline expression of tumour markers 
identified by immunohistochemistry and retrospectively assessed found two significant 
correlations for the HCC cohort. First, when taking into account histological grade and 
alcohol, low staining scores for the Ki67 proliferation marker were associated with 
higher PFS values (ie PFS > 16 weeks; p = 0.0207). Second, when taking into account 
time since diagnosis, increased expression of glycoprotein CD68 correlated with higher 
densities of macrophages in stroma and also with higher PFS values (p = 0.0324). No 
other investigated biomarkers were remarkable in this cohort or in the GC. No 
conclusion could be made regarding the RCC or OC due to the small number of 
patients between low and high PFS. 
 
 
Discussion 
The aim of this study was to evaluate tasquinimod activity in patients with solid tumours 
(liver, ovarian, gastric and renal cancers). At the time of protocol finalisation, 
tasquinimod had only been evaluated in prostate cancer. The study population 
selected included patients with advanced cancer types with a high unmet medical need 
reflecting high rates of treatment resistance. In addition, the four advanced cancer 
disease cohorts were selected because the immunomodulatory, antiangiogenic and 
antimetastatic properties of tasquinimod underpin a mechanism of action potentially 
beneficial in these advanced cancers, especially given the lack of standard second- or 
third-line systemic treatments for these patient populations. 
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The four cohorts can be viewed as separate proof-of-concept studies that were 
enrolled through a single protocol. While each cohort of patients was analysed 
separately for efficacy, the protocol allowed broader capture of information on 
exploratory end points. Notably, the study incorporated an early stopping design with 
futility analyses since, with limited data available regarding the efficacy of tasquinimod 
in other tumour types, exposure to a potentially ineffective drug should be kept 
minimised. 
The efficacy analysis revealed that the clinical activity of tasquinimod 
monotherapy was modest even in the HCC cohort, which proceeded to the second 
stage of the statistical design based on the T1 analysis. Tasquinimod, with its 
mechanism of action related to the microenvironment, showed no activity in the 
selected study population with advanced and resistant disease. In developing drugs of 
this type, it might be beneficial to evaluate them in patients with minimal residual 
disease as maintenance therapy after chemotherapy [9].  
In previous phase I and II clinical studies, tasquinimod was administered in 
escalating doses starting with 0.25 mg/day for 2 weeks, followed by 0.5 mg/day for 2 
weeks then, with acceptable tolerability, rising to 1.0 mg/day. In the current study, use 
of 0.5 mg/day as the starting dose allowed dose escalation earlier in the course of 
treatment and proved feasible. The majority of patients then received the higher dose 
of tasquinimod within a flexible dose regimen in which titration based on individual 
tolerability mitigated treatment-related toxicities. In this respect, the overall safety 
profile of tasquinimod was similar across the four cohorts and consistent with previous 
studies [10]. 
Alternatives to chemotherapy for advanced and resistant disease in the four 
malignancies included in this study are actively being sought and equally, further 
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research is needed to identify and validate biomarkers to monitor such new cancer 
treatments. The biomarkers results in this study are exploratory as there were no 
control group and few patients.  
In summary, adequate clinical activity of tasquinimod in patients with advanced 
HCC, OC, RCC and GC was not demonstrated in this study. The safety profile of 
tasquinimod across the four cancer patient cohorts was consistent with that previously 
reported in mCRPC and no new safety concerns were identified.  
  
Figure legends 
Figure 1. Patient disposition. ITT, intent to treat; TEAE, treatment-emergent adverse 
event.  
Figure 2. Kaplan-Meier estimates of (A) progression-free survival (PFS) based on 
central review and (B) overall survival (OS) for the hepatocellular cancer cohort. 
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Table 1. Summary of tasquinimod efficacy in all treated patients in separate cohorts with hepatocellular, ovarian, renal cell and 
gastric cancers.  
 
Variable Hepatocellular 
(N = 53)a 
Ovarian 
(N = 55) 
Renal cell 
(N = 38) 
Gastric 
(N = 21) 
     
PFS rate at T2b, n (%) [95% CI]     
 RECIST 1.1 criteria  14 (26.9) [15.6, 41.0] 4 (7.3) [2.0, 17.6] 5 (13.2) [4.4, 28.1] 2 (9.5) [1.2, 30.4] 
 Choi criteriac 11 (20.8) [10.8, 34.1] - - - 
P value for PFS rated 0.142 (RECIST 1.1) 
0.500 (Choi) 
1.00 0.800 0.630 
Clinical benefit, n (%) [95% CI]e 14 (26.4) [15.3, 40.3] 11 (20.0) [10.4, 33.0] 6 (15.8) [6.0, 31.3] 0 (0) 
PFS, median (95% CI) weeks 15.9 (8.0, 23.1) 8.0 (7.7, 17.4) 14.9 (7.9, 16.7) 6.0 (5.3, 7.3) 
OS, median (95% CI), range 
weeks 
29.3 (25.0, 38.7), 
1.1–89.4 
NC (30.7, NC),  
2.9–50.0 
32.7 (26.4, 40.9), 
3.4–53.0 
21.6 (13.9, 33.3), 
4.4–49.7 
aPFS rate based on RECIST 1.1 criteria at T2 for the hepatocellular cohort was reported on 52 patients (as planned in the protocol). 
bTiming of T2 as follows: hepatocellular 16 weeks; ovarian 24 weeks; renal cell 16 weeks; gastric 12 weeks.  
cChoi criteria were used for hepatocellular cancer cohort only. 
dP-values are based on the one-sided exact binomial test (to be compared to 0.1) for observed PFS rates compared with the 
expected PFS rates in the four cohorts: >20% (hepatocellular cancer and renal cancer), >35% (ovarian cancer), and >15% (gastric 
cancer). 
eA patient was considered to have had clinical benefit if a complete response, a partial response or stable disease was observed 
for ≥12 weeks after the first study medication according to RECIST criteria. OS, overall survival; NC, not calculated; PFS, 
progression-free survival; RECIST 1.1, Response Evaluation Criteria in Solid Tumours version 1.1. 
Table 2. Treatment-emergent adverse events of all severity grades according to system organ class (SOC) experienced by >10% 
patients in any cohort; n (%) values shown. 
SOC  
Preferred term 
Hepatocellular 
(n = 53) 
Ovarian 
(n = 55) 
Renal cell 
(n = 38) 
Gastric 
(n = 21) 
Any TEAE 53 (100) 55 (100) 38 (100) 21 (100) 
General disorders 47 (88.7) 44 (80.0) 22 (57.9) 17 (81.0) 
 Fatigue 32 (60.4) 31 (56.4) 8 (21.1) 15 (71.4) 
          Oedema peripheral 16 (30.2) 17 (30.9) 4 (10.5) 2 (9.5) 
 Asthenia 9 (17.0) 5 (9.1) 11 (28.9) 1 (4.8) 
 Pyrexia 3 (5.7) 8 (14.5) 1 (2.6) 1 (4.8) 
Gastrointestinal disorders 46 (86.8) 47 (85.5) 30 (78.9) 20 (95.2) 
 Nausea 21 (39.6) 24 (43.6) 12 (31.6) 14 (66.7) 
 Vomiting 19 (35.8) 16 (29.1) 9 (23.7) 14 (66.7) 
 Constipation 15 (28.3) 12 (21.8) 13 (34.2) 11 (52.4) 
 Abdominal pain 16 (30.2) 19 (34.5) 8 (21.1) 9 (42.9) 
 Diarrhoea 14 (26.4) 15 (27.3) 7 (18.4) 3 (14.3) 
 Upper abdominal pain 7 (13.2) 14 (25.5) 1 (2.6) 2 (9.5) 
 Gastro-oesophageal reflux 0 1 (1.8) 1 (2.6) 5 (23.8) 
           Dyspepsia 0 5 (9.1) 2 (5.3) 4 (19.0) 
           Abdominal distention 4 (7.5) 10 (18.2) 1 (2.6) 2 (9.5) 
           Ascites 6 (11.3) 1 (1.8) 0 0 
Metabolism and nutrition disorders 26 (49.1) 27 (49.1) 15 (39.5) 15 (71.4) 
 Decreased appetite 23 (43.4) 20 (36.4) 11 (28.9) 15 (71.4) 
 Hypoalbuminaemia 2 (3.8) 6 (10.9) 0 0 
Musculoskeletal and connective tissue 
disorders 
30 (56.6) 34 (61.8) 19 (50.0) 18 (85.7) 
 Back pain 9 (17.0) 14 (25.5) 6 (15.8) 11 (52.4) 
Pain in extremity 5 (9.4) 5 (9.1) 4 (10.5) 4 (19.0) 
 Arthralgia 5 (9.4) 10 (18.2) 2 (5.3) 3 (14.3) 
 Myalgia 2 (3.8) 6 (10.9) 4 (10.5) 2 (9.5) 
Musculoskeletal pain 3 (5.7) 4 (7.3) 4 (10.5) 2 (9.5) 
Investigations 21 (39.6) 22 (40.0) 6 (15.8) 11 (52.4) 
 Weight decreased 13 (24.5) 3 (5.5) 5 (13.2) 6 (28.6) 
Lipase increased 0 6 (10.9) 0 0 
 AST increased 4 (7.5) 6 (10.9) 1 (2.6) 2 (9.5) 
 ALT increased 3 (5.7) 6 (10.9) 0 2 (9.5) 
 Blood ALP increased 1 (1.9) 4 (7.3) 1 (2.6) 3 (14.3) 
Respiratory, thoracic and mediastinal 
disorders 
15 (28.3) 27 (49.1) 15 (39.5) 6 (28.6) 
Cough 5 (9.4) 13 (23.6) 9 (23.7) 3 (14.3) 
Dyspnoea 10 (18.9) 13 (23.6) 3 (7.9) 1 (4.8) 
Pleural effusion 1 (1.9) 6 (10.9) 2 (5.3) 0 
Infections and infestations 13 (24.5) 21 (38.2) 8 (21.1) 6 (28.6) 
Lower respiratory tract 0 0 6 (15.8) 3 (14.3) 
Urinary tract infection 1 (1.9) 8 (14.5) 0 2 (9.5) 
Oral candidiasis 1 (1.9) 2 (3.6) 1 (2.6) 3 (14.3) 
Psychiatric disorders 11 (20.8) 15 (27.3) 7 (18.4) 8 (38.1) 
Insomnia 9 (17.0) 9 (16.4) 6 (15.8) 6 (28.6) 
Nervous system disorders 17 (32.1) 18 (32.7) 16 (42.1) 6 (28.6) 
 Headache 9 (17.0) 10 (18.2) 4 (10.5) 1 (4.8) 
Lethargy 0 2 (3.6) 5 (13.2) 1 (4.8) 
Dizziness 2 (3.8) 6 (10.9) 4 (10.5) 1 (4.8) 
Blood and lymphatic system 5 (9.4) 9 (16.4) 4 (10.5) 5 (23.8) 
Anaemia 4 (7.5) 9 (16.4) 4 (10.5) 5 (23.8) 
Vascular disorders 5 (9.4) 2 (3.6) 5 (13.2) 3 (14.3) 
Hypotension 1 (1.9) 1 (1.8) 5 (13.2) 1 (4.8) 
Injury, poisoning and procedural 
complications 
2 (3.8) 5 (9.1) 4 (10.5) 3 (14.3) 
Fall 0 4 (7.3) 0 3 (14.3) 
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; SOC, system organ class; TEAE, 
treatment-emergent adverse event. 
 
Enrollment
Allocation
Post-study follow-up
Excluded (n = 34):
• not meeting inclusion criteria 
(n = 29)
• AE (n = 2)
• other reasons (n = 3)
Assessed for eligibility (n = 201)
Enrolled (n = 167)
Hepatocellular cancer
(n = 53)
• Received study treatment 
(n = 53)
• Withdrew from treatment
(n = 50):
– TEAE (n = 10)
– withdrew consent (n = 2)
– disease progression 
(n = 38)
Ovarian cancer (n = 55)
• Received study treatment 
(n = 55)
• Withdrew from treatment 
(n = 52):
– TEAE (n = 5)
– withdrew consent (n = 3)
– disease progression 
(n = 44)
Renal cell cancer (n = 38)
• Received study treatment 
(n = 38)
• Withdrew from treatment 
(n= 38)
– TEAE (n = 8)
– disease progression 
(n = 30)
Gastric cancer (n = 21)
• Received study treatment 
(n = 21)
• Withdrew from treatment 
(n= 21):
– TEAE (n = 1)
– disease progression 
(n = 20)
• Entered follow-up phase 
(n = 49)
• Stopped follow-up (n = 40):
– withdrew consent (n = 1)
– died (n = 38)
– lost to follow-up (n = 1)
• Entered follow-up phase 
(n = 48)
• Stopped follow-up (n = 23):
– died (n = 22)
– lost to follow-up (n = 1)
• Entered follow-up phase 
(n = 37)
• Stopped follow-up (n = 23):
– died (n = 22)
– withdrew consent (n = 1)
• Entered follow-up phase 
(n = 21)
• Stopped follow-up (n = 16):
– died (n = 16)
• ITT and safety population 
(n = 53)
• ITT and safety population
 (n = 55)
• ITT and safety population 
(n = 38)
• ITT and safety population 
(n = 21)
Analysis
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A. Median PFS: 15.9 weeks (95% CI: 8.00, 23.14)
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B. Median OS: 29.3 weeks (95% CI: 25.00, 38.71)
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